Seeking Alpha

Eli Lilly's (LLY -2.2%) Forteo and risedronate, which is marketed by Warner Chilcott (WCRX...

Eli Lilly's (LLY -2.2%) Forteo and risedronate, which is marketed by Warner Chilcott (WCRX +3.85%) and Sanofi (SNY +0.8%), go head to head in a Phase III trial of postmenopausal women with osteoporotic vertebral fractures and come out equal in the main goal of achieving a 30%+ fall in the worst back pain. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs